TUM – Technical University of Munich Menü

Prof. Dr. Wolfgang Weber


Nuclear Medicine

Academic Career and Research Areas

Professor Weber (b. 1967) is Director of the Department of Nuclear Medicine at “Klinikum rechts der Isar” (the University Hospital of the TUM) since 2018. He specializes in the field of molecular imaging and targeted radionuclide therapy. His research focus is the combination imaging and therapy of cancer (theranostics).

Professor Weber obtained his doctorate at the TUM in 1995. He then worked as an associate professor at the University of California, Los Angeles from 2003-2007. In 2007, he became Chair of the Department of Nuclear Medicine at the University of Freiburg. From 2013-2017 he was Chief of the Molecular Imaging and Therapy service at Memorial Sloan Kettering Cancer Center and Professor of Radiology at Weill-Cornell Medical College, New York.

    Key Publications

    Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U: "Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging". Journal of Clinical Oncology. 2001; 19 (12):3058-3065.


    Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W: "Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors". Clinical Cancer Research, 2006; 12 (19):5659-67.


    Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA: "Noninvasive Imaging of alphaVbeta3 Function as a Predictor of the Antimigratory and Antiproliferative Effects of Dasatinib". Cancer Research. 2009; 69 (7):3173-3179.


    Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA: "Comparison of Somatostatin Receptor Agonist and Antagonist for Peptide Receptor Radionuclide Therapy: A Pilot Study". Journal of Nuclear Medicine. 2014; 55 (8):1248-1252.


    Nagarajah J, Le M, Knauf JA, Ferrandino G, Montero-Conde C, Pillarsetty N, Bolaender A, Irwin C, Krishnamoorthy GP, Saqcena M, Larson SM, Ho AL, Seshan V, Ishii N, Carrasco N, Rosen N, Weber WA, Fagin JA: "Sustained ERK inhibition maximizes responses of BrafV600E thyroid cancers to radioiodine". Journal of Clinical Investigation. 2016; 126 (11):4119-4124.